$19.25
-0.05 (-0.26%)
NOV News30 articles
SLB Shares Decline Amid Oil Price Drop Despite Indonesian Gas Contract
SLB shares dropped 1.8% to $50.64 as oil prices declined, overshadowing new offshore drilling contracts for a deepwater gas project in Indonesia targeting first production by 2028.
Novavax Shares Surge on Pfizer Deal, Vaccine Strategy Shift
Novavax shares surged 13% Friday after Q1 revenue of $139.5 million beat estimates, fueled by a $30 million Pfizer licensing deal for Matrix-M adjuvant.
GE Vernova Slides after Texas Nuclear-Gas AI Power Deal
GE Vernova shares dropped over $70 after announcing a Texas nuclear-gas project for AI data centers, as investors digest strong Q1 orders.
Novavax Surges on Pfizer Deal, Q1 Revenue Beat Despite Weak Vaccine Sales
Novavax reported Q1 revenue of $139.5M, beating estimates, driven by $30M from Pfizer's Matrix-M license. Shares rose further as licensing income offset weak COVID vaccine sales.
Novavax Surges on Pfizer Deal, Beats Q1 Revenue Forecasts
Novavax topped Q1 revenue estimates at $139.5M, driven by a $30M Pfizer payment, offsetting weak COVID vaccine sales. Shares rose 15.6%.
Novo Nordisk Shares Surge on Strong Wegovy Pill Sales, Upgraded 2026 Outlook
Novo Nordisk raised its 2026 guidance after Wegovy pill prescriptions topped 2 million, sending shares up 9.2%. The company now expects a smaller decline in sales and profit this year.
Cenovus Energy Gains Pre-Earnings as MEG Integration Takes Spotlight
Cenovus Energy shares rose 2.9% to C$40.96 ahead of Q1 results, as CIBC reaffirmed an outperform rating and a C$46 target, highlighting the first full quarter with MEG Energy assets.
Intel's SambaNova Investment Clears Antitrust Hurdle Amid AI Chip Surge
Intel's SambaNova investment cleared U.S. antitrust review, removing a key barrier as INTC stock approaches $100 on AI demand.
Baxter Shares Rise on Q1 Beat; Novum Pump Issues Loom Over 2026 Outlook
Baxter topped Q1 earnings expectations, sending shares up 4%, but the company's 2026 outlook remains unchanged amid ongoing Novum pump challenges and tariff pressures.
Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data
Eli Lilly's Foundayo prescriptions hit 3,707 in week two, well behind Novo Nordisk's Wegovy. Lilly shares dropped 4%, while Novo gained 6%. Analysts advise caution on early figures.
Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race
Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly's Foundayo at 3,707, according to IQVIA data. Novo shares rose, Lilly fell.
GE Vernova Boosts Outlook on AI Data Center Power Demand Surge
GE Vernova increased its 2026 revenue guidance following a surge in first-quarter orders, propelled by accelerating demand from artificial intelligence data centers for power infrastructure.
Enovix Surges 12% Amid Analyst Shifts; Indian Markets Slump on Oil Spike
Enovix shares rallied nearly 12% on Monday despite below-average volume and divergent analyst views. Meanwhile, Indian equity indices tumbled over 800 points as Brent crude surged past $111, stoking inflation fears.
GE Vernova Shares Slip Despite Strong Gas Demand and $40B Nuclear Deal
GE Vernova shares declined 4% Monday, even as the company highlighted a significant jump in gas turbine orders and a potential $40 billion small modular reactor deal stemming from a U.S.-Japan energy pact.
Aurora Innovation's $10B Valuation Faces Reality Check as Driverless Truck Rollout Advances
Aurora Innovation shares declined 2.6% to $4.12, valuing the autonomous trucking company at nearly $10 billion despite generating only $3 million in 2025 revenue. The firm aims to deploy over 200 driverless trucks by year-end while navigating a $238 million quarterly operating loss.
Fundrise Innovation Fund Soars 55% in NYSE Debut as Retail Flocks to Private AI
Fundrise Innovation Fund shares skyrocketed 54.5% to $117.70 in their second day of NYSE trading, valuing the fund at more than six times its March 2 net asset value. The closed-end fund provides retail access to private artificial intelligence companies.
Novo Nordisk Shares Dip Despite FDA Nod for Higher-Dose Wegovy
Novo Nordisk shares declined in Copenhagen trading even after U.S. regulators cleared a higher-dose version of its Wegovy obesity treatment. Competitive pressures from Eli Lilly and looming generic competition in India weighed on investor sentiment.
Hims & Hers Stock Stabilizes as Novo Deal Shifts Focus to Profitability
Hims & Hers Health shares traded near $23.82 Friday, stabilizing after a week of volatility driven by its new branded obesity drug agreement with Novo Nordisk. The shift from compounded medications raises margin concerns despite reducing regulatory risk.
Cenovus Energy Reaches 52-Week Peak Amid Oil Supply Fears
Cenovus Energy shares climbed 4.6% to C$32.18, hitting a 52-week high as crude prices neared $100 a barrel. The company projects 2026 upstream output could reach 985,000 barrels of oil equivalent per day.
Cenovus Energy Reaches 52-Week Peak Amid Oil Price Surge
Cenovus Energy shares surged to a 52-week high as Brent crude oil prices topped $100 per barrel, driven by renewed Middle East conflicts. The company's significant debt and planned operational turnarounds underscore its exposure to volatile energy markets.
Hims & Hers Stock Extends Rally on Novo Nordisk Patent Settlement
Shares of Hims & Hers Health continued their ascent following a resolution to a patent conflict with Novo Nordisk, which will reintroduce branded GLP-1 medications to its service. Analysts have upgraded the stock but caution about potential margin pressures.
Hims & Hers Soars on Novo Nordisk Partnership, Analyst Targets Rise
Shares of Hims & Hers Health skyrocketed approximately 49% over two sessions following a new distribution agreement with Novo Nordisk. The deal resolves a legal dispute and will bring branded GLP-1 drugs to the telehealth platform, leading several analysts to raise their price targets.
GE Vernova Commits $200M to Vietnam Transformer Plant Amid Energy Push
GE Vernova will invest approximately $200 million to establish a large power transformer plant in Hai Phong, Vietnam, with full operations targeted for 2028. The move aligns with Vietnam's accelerated LNG and grid infrastructure development.
Hims & Hers Shares Jump on Novo Nordisk Partnership Revival
Hims & Hers Health shares surged in premarket trading Monday following reports that Novo Nordisk will resume selling its weight-loss drugs through the telehealth platform. The move marks a reversal from a patent dispute last month.
GE Vernova Secures Major Italian Wind Contract, Expands Grid Component Plant
GE Vernova has secured a contract to supply 17 onshore wind turbines for a project in southern Italy, with deliveries starting in 2027. Concurrently, the company is investing $30 million to expand its electrification component plant near Milan.
GE Vernova Gains on Italian Wind Deal and $30M Grid Plant Investment
GE Vernova's stock advanced following new Italian contracts for wind turbines and grid equipment, alongside a $30 million manufacturing expansion near Milan.
FDA Issues Second Ozempic Ad Warning to Novo Nordisk in Escalating Scrutiny
The FDA has sent Novo Nordisk a second advertising violation notice in under a month, citing misleading claims for Ozempic. The agency simultaneously warned 30 telehealth companies about compounded GLP-1 drug promotions.
GE Vernova Shares Slide 5% Amid Broad Market Sell-Off
GE Vernova shares declined approximately 5% on Tuesday, underperforming a broader market downturn. The power equipment firm detailed a $30 million expansion in Italy and finalized the sale of its Proficy software unit.
GE Vernova Dips Amid Inflation, Fed Focus; Wind Project Risks Loom
GE Vernova stock declined slightly Friday as broader markets fell on higher-than-expected wholesale inflation. Investors are now focused on upcoming jobs data and Federal Reserve signals.
Hims & Hers Faces SEC Probe, Novo Nordisk Lawsuit as Analysts Cut Targets
Hims & Hers Health shares held steady premarket following disclosures of an SEC probe and a patent lawsuit from Novo Nordisk. Analysts at BTIG and Citi downgraded the stock, citing regulatory risks.